Faraday Pharmaceuticals: Elemental reducing agents for critical care treatment to prevent cardiac and skeletal muscle loss: lead candidate FDY-5301 Ph 3 (pivotal) to initiate mid-2020 for reperfusion injury following heart attack (AMI); data early 2023. SPA submission received by FDA Jan 22, 2020 and initial feedback received Feb 2020 - Type A meeting requested. Ph 2 recruitment completed for muscle weakness following total knee replacement; data in 1Q20. Ph 2 ready for ICU-acquired weakness following trauma; first patient dosed expected 2Q20. Significant additional treatment applications with limited to no competition. $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase III
Disease Space
Cardiovascular
Industry
Biotechnology, Pharmaceuticals
Listing
Private
Website:
Address:
1616 Eastlake Ave E
Suite 560
Seattle, WA 98102
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.